ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag protest genetics genomics

Misguided Expectations?
Franklin Hoke | Dec 11, 1994 | 8 min read
Manufacturer Up In Arms Incensed that the terms exclude industrial scientists, Merck announces sponsorship of competing project A powerful new, privately held database of human complementary DNA (cDNA) sequences has become available to researchers eager to test its capabilities to rapidly identify new genes. The proposed terms of access to the database, however, exclude pharmaceutical and other industry-affiliated scientists, angeri
Limited Access To cDNA Database Has Drug Manufacturer Up In Arms
Franklin Hoke | Dec 11, 1994 | 8 min read
Date : December 12, 1994 Incensed that the terms exclude industrial scientists, Merck announces sponsorship of competing project A powerful new, privately held database of human complementary DNA (cDNA) sequences has become available to researchers eager to test its capabilities to rapidly identify new genes. The proposed terms of access to the database, however, exclude pharmaceutical and other industry-affiliated scientists, an
Misguided Expectations?
Franklin Hoke | Dec 11, 1994 | 8 min read
Manufacturer Up In Arms Incensed that the terms exclude industrial scientists, Merck announces sponsorship of competing project A powerful new, privately held database of human complementary DNA (cDNA) sequences has become available to researchers eager to test its capabilities to rapidly identify new genes. The proposed terms of access to the database, however, exclude pharmaceutical and other industry-affiliated scientists, angeri
Limited Access To cDNA Database Has Drug Manufacturer Up In Arms
Franklin Hoke | Dec 11, 1994 | 8 min read
Date : December 12, 1994 Incensed that the terms exclude industrial scientists, Merck announces sponsorship of competing project A powerful new, privately held database of human complementary DNA (cDNA) sequences has become available to researchers eager to test its capabilities to rapidly identify new genes. The proposed terms of access to the database, however, exclude pharmaceutical and other industry-affiliated scientists, an
Notebook
The Scientist Staff | Apr 26, 1998 | 8 min read
WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were

Run a Search

ADVERTISEMENT